Quick Answer
Tango Therapeutics, Inc. reported Stockholders Equity of $346.18 million for fiscal year 2025.
Tango Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $346.18M | +73.5% |
| 2024 | $199.52M | -21.2% |
| 2023 | $253.11M | +1.5% |
| 2022 | $249.48M | -27.6% |
| 2021 | $344.75M | +793.1% |
| 2020 | $38.60M | +388.3% |
| 2019 | $7.91M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $160.03M | -30.2% | +18.6% |
| June 30, 2025 | $134.95M | -45.5% | -19.1% |
| March 31, 2025 | $166.76M | -36.9% | -16.4% |
| December 31, 2024 | $199.52M | -21.2% | -12.9% |
| September 30, 2024 | $229.17M | -17.1% | -7.5% |
| June 30, 2024 | $247.67M | +16.3% | -6.3% |
| March 31, 2024 | $264.45M | +16.4% | +4.5% |
| December 31, 2023 | $253.11M | +1.5% | -8.5% |
- Tango Therapeutics, Inc. showed an increase of +73.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Tango Therapeutics, Inc.’s stockholders equity has grown by 4279.2% (from $7.91 million to $346.18 million).
- The most recent figure is from Tango Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: